Intellia Therapeutics (NTLA) AI Stock Analysis

• Market Cap: $1.10B
• Dividend Yield: N/A
• Average Volume (3M): 4.85M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.48
• Revenue Growth: 14.99%
• EPS Growth: 14.42%
• Country: US
• Employees: 403
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.98
• Shares Outstanding: 107,346,886
• 10 Day Avg. Volume: 5,141,620
• 30 Day Avg. Volume: 4,847,540
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.56
• Enterprise Value/Revenue: 11.65
• Enterprise Value/Gross Profit: 12.91
• Enterprise Value/Ebitda: -1.23
• 1Y Price Target: $27.67
• Price Target Upside: 171.01% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 20

• Rating: 53 Neutral
• Price Target: $11.00 ▲(7.74% Upside)

Intellia Therapeutics' overall stock score reflects a challenging financial environment typical of early-stage biotech firms, with high R&D expenses and negative cash flows. However, strong clinical progress and a solid cash position provide a positive outlook. Technical indicators and valuation metrics present a mixed picture, with profitability challenges offset by potential future growth.

Positive Factors

Clinical Trials

Enrollment in the Ph3 MAGNITUDE trial is tracking to enroll at least 650 patients, ahead of previous goals.

Financial Position

NTLA ended 2Q25 with $630.5M in cash, providing a strong financial position.

Regulatory Progress

The company is on track to submit a BLA, indicating progress towards regulatory approval.

Negative Factors

Price Target Adjustments

The price target for the stock has been slightly decreased.

Product Launch Delays

The launch of a key product has been delayed based on management commentary.

Risks in Clinical Trials

Risks include unexpected deterioration of efficacy at the Phase 1/2 update for NTLA-2002 in HAE or for Phase 1 of Nex-Z in ATTR-CM and/or ATTR-PN.

Intellia Therapeutics Business Overview & Revenue Model

Company Description

Intellia Therapeutics, Inc. (NTLA) is a biotechnology company focused on developing transformative therapies using its proprietary CRISPR/Cas9 gene-editing technology. The company operates in the healthcare sector, primarily in the field of genetic medicine, targeting a range of diseases including genetic disorders, cancers, and other serious conditions. Intellia's core products and services revolve around its innovative gene-editing platform, which aims to provide one-time curative treatments by directly addressing the root causes of diseases at the genetic level.

How the Company Makes Money

Intellia Therapeutics generates revenue through several key streams. Primarily, the company earns money by developing and advancing its therapeutic candidates through clinical trials and subsequently partnering with larger pharmaceutical companies for commercialization. These partnerships often involve upfront payments, research funding, and milestone payments based on the achievement of specific development goals. Additionally, Intellia may receive royalties on sales of products that emerge from these collaborations. The company also benefits from government grants and research funding aimed at advancing gene-editing technologies. Significant partnerships with major firms in the pharmaceutical industry further contribute to Intellia's revenue model, providing financial support and shared resources for the development of its therapies.

Intellia Therapeutics Financial Statement Overview

Summary

Intellia Therapeutics is in a typical growth and development phase for a biotech company, characterized by high R&D expenses leading to net losses and negative cash flows. While the company maintains a strong cash position, its revenue has dwindled, and its balance sheet reflects declining shareholder equity. The financials suggest the firm is investing heavily in its pipeline, which is common in biotechnology, but it faces significant risks related to its future revenue generation and profitability.

Income Statement

Intellia Therapeutics has faced a challenging financial environment, with declining revenues from $57.99 million in 2020 to $36.27 million in 2023, and ultimately to zero in 2024. The company has consistently incurred net losses, with a significant net loss of $519.02 million in 2024, indicating high operational costs and low revenue, characteristic of a biotech firm in early stages of development.

Balance Sheet

The balance sheet shows adequate cash reserves with $601.52 million in cash and equivalents. However, the debt-to-equity ratio stands at 0.24, indicating manageable leverage, but the persistent decrease in stockholders' equity from $1.05 billion in 2023 to $871.96 million in 2024 suggests a deterioration in shareholder value. The equity ratio is relatively stable, providing a moderate level of financial stability.

Cash Flow

The cash flow statement highlights negative free cash flow each year, with a free cash flow of -$408.07 million in 2024, driven by high operating cash outflows. The operating cash flow to net income ratio is unfavorable due to consistent losses, signaling inefficiencies in cash generation relative to expenses. This is typical for a biotech firm still in development phases.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	52.86M	57.88M	36.27M	52.12M	33.05M	57.99M
Gross Profit	47.68M	47.59M	27.30M	44.55M	26.16M	-92.41M
EBITDA	-501.87M	-523.98M	-506.31M	-450.59M	-260.96M	-130.27M
Net Income	-480.19M	-519.02M	-481.19M	-474.19M	-267.89M	-134.23M
Balance Sheet
Total Assets	898.89M	1.19B	1.30B	1.52B	1.29B	676.32M
Cash, Cash Equivalents and Short-Term Investments	459.65M	601.51M	912.22M	1.19B	748.69M	597.37M
Total Debt	102.59M	210.20M	115.35M	130.70M	74.02M	39.30M
Total Liabilities	183.64M	319.06M	250.81M	284.53M	254.22M	149.25M
Stockholders Equity	715.25M	871.96M	1.05B	1.24B	1.04B	527.07M
Cash Flow
Free Cash Flow	-421.82M	-354.66M	-408.07M	-391.68M	-237.79M	-53.50M
Operating Cash Flow	-418.58M	-348.88M	-394.09M	-333.29M	-225.03M	-49.91M
Investing Cash Flow	345.09M	125.57M	-31.35M	160.31M	-550.78M	-214.49M
Financing Cash Flow	99.16M	185.75M	130.32M	582.96M	736.69M	371.78M

Intellia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 10.21
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Negative. The current price of 10.21 is below the 20-day moving average (MA) of 11.39, below the 50-day MA of 10.96, and below the 200-day MA of 10.62, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 38.35 is Neutral, neither overbought nor oversold. The STOCH value of 17.51 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NTLA.

Intellia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTLA	53 Neutral	$1.10B	―	-56.95%	―	14.99%	14.42%
ARVN	52 Neutral	$524.20M	―	-35.41%	―	―	―
NRIX	52 Neutral	$752.26M	―	-50.67%	―	41.86%	10.48%
Sector *	51 Neutral	$7.77B	-0.12	-39.07%	2.21%	22.68%	-1.42%
VIR	51 Neutral	$605.68M	―	-46.22%	―	-75.91%	-12.11%
XNCR	43 Neutral	$541.34M	―	-29.22%	―	-2.07%	22.52%
RCKT	40 Underperform	$314.00M	―	-69.65%	―	―	10.36%

Intellia Therapeutics Corporate Events

Intellia Therapeutics Announces Executive Retirement

On August 7, 2025, Intellia Therapeutics announced the upcoming retirement of Dr. David Lebwohl, the company’s Executive Vice President and Chief Medical Officer, effective August 7, 2026. The company also reported strong progress in its clinical trials, including the Phase 3 MAGNITUDE trial for ATTR with cardiomyopathy and the Phase 3 HAELO study for hereditary angioedema, both of which are ahead of schedule. The company ended the second quarter with $630.5 million in cash and is expected to fund operations into the first half of 2027, indicating a robust financial position to support its ongoing and future projects.

Intellia Therapeutics Announces Positive Phase 1 Trial Data

On June 15, 2025, Intellia Therapeutics announced positive three-year data from the Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress. The trial showed a 98% mean reduction in monthly HAE attack rates with a single dose, and the treatment was well-tolerated with no serious adverse events. The ongoing global Phase 3 HAELO trial has completed screening ahead of schedule, and Intellia plans to present further data in 2025, with a U.S. launch expected in 2027, pending FDA approval.

Intellia Therapeutics Holds Annual Stockholders’ Meeting

On June 11, 2025, Intellia Therapeutics held its annual stockholders’ meeting, where several key decisions were made. The stockholders approved the 2025 Equity Incentive Plan, elected three directors for a three-year term, ratified Deloitte & Touche LLP as the independent auditor for 2025, and decided on an annual frequency for advisory votes on executive compensation. These decisions are expected to impact the company’s governance and operational strategies.

Intellia Therapeutics Updates on Phase 3 Study Progress

On May 28, 2025, Intellia Therapeutics provided a business update on its Phase 3 studies. The HAELO study for NTLA-2002 in hereditary angioedema and the MAGNITUDE-2 study for nex-z in ATTRv-PN are progressing well, with anticipated U.S. commercial launches in 2027 and 2029, respectively. The MAGNITUDE study for ATTR-CM is also on track, with over 200 patients dosed and expected enrollment completion by early 2027. Adverse events reported in the MAGNITUDE study have been consistent with earlier phases, with one recent case of asymptomatic liver transaminase elevations resolving without intervention.

Intellia Therapeutics Reports Positive Phase 1 Trial Results

On May 18, 2025, Intellia Therapeutics announced positive two-year follow-up data from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). The study showed a significant reduction in serum TTR levels and clinically meaningful improvements in neuropathic impairment measures, with no serious adverse events, indicating potential for nex-z as a one-time treatment. The results were presented at the Peripheral Nerve Society Annual Meeting, highlighting the drug’s potential to improve outcomes for patients who previously showed disease progression on patisiran.